Editorial: Cell death in cancer immunology
Laura Mondragón,Shensi Shen,Laura Senovilla
DOI: https://doi.org/10.3389/fonc.2024.1504738
IF: 4.7
2024-11-27
Frontiers in Oncology
Abstract:The relationship between cell death and cancer immunology has been studied for decades with different approaches, as cell death plays a crucial immunomodulatory role in tumor initiation, progression and metastasis [1]. Research has focused on understanding the immune system's role in tumor cell resistance to cell death; discerning how cell death paradoxically promotes immunosuppression and tumor progression; explaining the mechanisms by which cell death induces tumor immunogenicity; studying the immunomodulatory effects of dead or dying tumor cells on tumor microenvironment; and investigating how various immunotherapies trigger tumor cell death.Given the complex interplay between cancer immunology and cell death, this collection of fifteen articles highlights the latest advances in the field through three reviews and twelve original studies. These works can be categorized into two main axes: 1) the development of prognostic models using machine learning, multiomics and patient datasets, and 2) the identification and validation of new biomarkers and therapies focused on the activation of the immune system.In the last decades, the rise of "omic" technologies has enabled the development of clinical prediction models aimed at improving medical decision-making, enhancing patient's outcomes, and identifying novel biomarkers and therapeutic targets. In the ongoing quest for better treatments and ways to overcome cancer cell death resistance and immune evasion, new cell death mechanisms linking these processes have been discovered, offering fresh new strategies to combat cancer. This is the case of disulfidptosis, a recently described new form of cell death caused by disulfide stress [2]. Disulfides are produced in response to oxidative stress to help maintain the secondary, tertiary, and quaternary structures of proteins by acting as interand intra-subunit cross-links. Excessive intracellular accumulation of disulfides solute carrier family 7 member 11 (SLC7A11) induces, together with glucose starvation, aberrant disulfide bonds formation between actin cytoskeleton, causing its collapse in a particular and orderly manner. Overexpression of SLC7A11 and GLUT inhibitors has proved to inhibit tumor growth, which may contribute to the development of a new therapeutic strategy against cancer.Consequently, multiple works have been undertaken to answer these questions in the last months, mostly by predictive models development. In this sense, Ming Li et al. make use of 20 diagnosed-related groups (DRGs) and LASSO and Cox regression analysis to provide, among other cell infiltration patterns, a new potential therapeutic target: POU Class 4 Homeobox 1 (POU4F1), which promotes cell proliferation, migration and, most importantly, disulfidptosis in colon adenocarcinoma (COAD) patients. In a broader application, Jin Wang et al. also develop a similar analysis making use of disulfidptosisrelated genes identified from CRISPR-Cas9 screenings leading to the identification of neuronal acetylcholine receptor subunit alpha-5 (CHRNA5) as a potential therapeutic target due to its impact on cell proliferation, migration, and disulfidptosis in the context of lung adenocarcinoma (LUAD). Finally, Kai Zhang et al. focused on Methods Public datasets to develop a prognostic model for LUAD to predict patient's survival and the efficacy of immune checkpoint blockage considering the expression of disulfidptosisrelated genes.Ti Yang et al. also explore disulfidptosis and immune microenvironment to develop a new prognostic model to identify therapeutic targets for hepatocellular carcinoma (HCC) utilizing bulk ribonucleic acid (RNA) sequencing, spatial transcriptomic (ST) and singlecell RNA sequencing. Their findings reveal that N-myc downregulated gene 1 (NDRG1) influences macrophage differentiation and enables tumor cells to evade the immune system. Similarly, Haishui Zheng et al. leverage RNA sequencing data and clinical information from HCC patients in the The Cancer Genome Atlas (TCGA) to create a predictive model for chemotherapy sensitivity and immunotherapy efficacy in HCC.To finish the first axis, ferroptosis, a form of cell death dependent on iron and characterized by the accumulation of lipid peroxides, and fatty acid metabolism (FAM) in the tumor microenvironment (TME), is reviewed by Ke Guo et al. in the context of ovarian cancer and its role in tumor suppression [3,4]. Ferroptosis role in the onset, progression, and incidence of ovarian cancer and their synergy with immunotherapy is defined together with new potential treatments based on these facts. Then, Junchang Zhu et al. explore the relationship between ferroptosis and patients outcome in colorectal cancer (CRC) with the objective of anticipating immunotherapy effectiveness. They make use of TCGA and GEO databases to create the FeFAMscore, which proved that ferroptosis regulators and FAM-related genes not only enhance immune activa -Abstract Truncated-
oncology